Quetiapine in patients with borderline personality disorder: An open-label trial

Annals of Clinical Psychiatry

Volumn 20, Issue 4, 2008, Pages 219-226

  Adityanjee, ^a,b   Romine, Ann ^a   Brown, Eric ^a,c   Thuras, Paul ^a,c   Lee, Susanne ^a   Schulz, S Charles ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ODMH Northcoast Behavioral Healthcare   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Borderline personality disorder; Dosing; Outpatients; Quetiapine

Indexed keywords

QUETIAPINE;

ADULT; AKATHISIA; APPETITE DISORDER; ARTICLE; BARRATT IMPULSIVITY SCALE; BORDERLINE STATE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HUMAN; IRRITABILITY; LOW DRUG DOSE; MALE; NOSE CONGESTION; PRIORITY JOURNAL; RATING SCALE; SCHEDULE FOR INTERVIEWING BORDERLINES; SEDATION; SIDE EFFECT; SYMPTOM CHECKLIST 90; TONGUE EDEMA; TREATMENT DURATION; VIVID DREAM; WEIGHT GAIN; XEROSTOMIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; APPETITE; AROUSAL; BORDERLINE PERSONALITY DISORDER; BRIEF PSYCHIATRIC RATING SCALE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PERSONALITY ASSESSMENT;

EID: 57149139518     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230802467545     Document Type: Article

References (38)

1. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233-246.
2. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-121.
3. Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351-1360.
4. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54(6):549-557.
5. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68.
6. Meats P Quetiapine ("Seroquel"): An effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Practice 1997;1: 231-239.
7. Schulz SC, Thomson R, Brecher M The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res 2003;62(1-2):1-12.
8. Brecher M, Rak, I., Melvin, K., Jones A.M. The long-term effect of quetiapine ("Seroquel") monotherapy patients with schizophrenia. Int J Psychiatry Clin Practice 2000;4:287-291.
9. Torgerson G, Kringelen, E., Cramer, V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001;58:590-596.
10. American_Psychiatric_Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association; 1994.
11. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991;48(12):1060-1064.
12. Blum N, Pfohl B, John DS, Monahan P, Black DW. STEPPS: A cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder - a preliminary report. Compr Psychiatry 2002;43(4):301-310.
13. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54(12):1081- 1088.
14. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991;148(8):1064-1067.
15. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002;159(12):2048-2054.
16. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15(1):23-29.
17. Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995;31(4):773-777.
18. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63(5):442-446.
19. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51(3): 333-343.
20. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004;6(1):66-70.
21. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43(7):680-686.
22. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986;43(7):691-697.
23. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63(3):241-244.
24. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65(1):104-109.
25. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46(10):1429-1435.
26. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62(11):849-854.
27. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006;163(5):833-838.
28. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005;66(10):1298-1303.
29. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003;4(1):42-44.
30. Gruettert T, Friege, L. Quetiapine in patients with borderline personality disorder and psychosis: a case series. International Journal of Psychiatry in Clinical Practice 2005;9(3):180-186.
31. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006;67(7):1042-1046.
32. Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007;8(14):2207-2213.
33. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):158-163.
34. Overall JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:199-812.
35. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
36. Barratt ES. Anxiety and impulsiveness related to psychomotor efficiency. Percept Mot Skills 1959; 9:191-198.
37. Baron M, Asnis, L., Gruen, R. Schedule of interviewing schizotypal personalities: A diagnostic interview for schizotypal features. Psychiatry Res 1981;4:213-228.
38. Schulz SC, Camlin, KL, Berry, SA Friedman, L. A double-blind study of risperidone for BPD (NR270). In: 151st Annual Meeting of the American Psychiatric Association, 1998; Toronto, Ontario, Canada.